CoChat

Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake

The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.

Abstract

Obesity is a growing epidemic, and current medical therapies have proven inadequate. Endogenous satiety hormones provide an attractive target for the development of drugs that aim to cause effective weight loss with minimal side effects. Both glucagon and GLP-1 reduce appetite and cause weight loss. Additionally, glucagon increases energy expenditure. We hypothesized that the combination of both peptides, administered at doses that are individually subanorectic, would reduce appetite, while GLP-1 would protect against the hyperglycemic effect of glucagon. In this double-blind crossover study, subanorectic doses of each peptide alone, both peptides in combination, or placebo was infused into 13 human volunteers for 120 min. An ad libitum meal was provided after 90 min, and calorie intake determined. Resting energy expenditure was measured by indirect calorimetry at baseline and during infusion. Glucagon or GLP-1, given individually at subanorectic doses, did not significantly reduce food intake. Coinfusion at the same doses led to a significant reduction in food intake of 13%. Furthermore, the addition of GLP-1 protected against glucagon-induced hyperglycemia, and an increase in energy expenditure of 53 kcal/day was seen on coinfusion. These observations support the concept of GLP-1 and glucagon dual agonism as a possible treatment for obesity and diabetes.

Overview

Integrity signals

Registry

Crossref · 10.2337/db14-0242

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 47 references

Cited by

See all 161

Metadata

Authors
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., Minnion, J., Cuenco, J., Ghatei, M. A., Meeran, K., Tan, T. M., & Bloom, S. R.
Affiliations
Imperial College London (GB)
Corresponding author
Bloom, Stephen R.
Venue
Diabetes
Published
2014-10-13
Volume
63
Issue
11
Pages
3711-3720
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2115939390
Cited by
159
References
49
Citations by year
2026: 9 · 2025: 13 · 2024: 19 · 2023: 14 · 2022: 10 · 2021: 15 · 2020: 13 · 2019: 12 · 2018: 16 · 2017: 11 · 2016: 9 · 2015: 17 · 2014: 1
FWCI
6.17
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Wellcome Trust
  • National Institute for Health and Care Research (ACF-2007-21-023, ACF-2010-21-012, ACF-2010-21-017)
  • Imperial College Healthcare NHS Trust
  • National Institutes of Health
  • Medical Research Council (MR/J010936/1, MR/K02115X/1, MR/K023667/1, MR/J010731/1)
  • Biotechnology and Biological Sciences Research Council
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
glucagon-like peptide-1, glucagon, dietary intake, appetite, obesity, weight loss, satiety hormones, energy expenditure, hyperglycemia, diabetes treatment
MeSH terms
Adult, Eating, Glucagon, Humans, Hyperglycemia, Male, Cross-Over Studies, Glucagon-Like Peptide 1, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake. https://app.cochat.ai/papers/10.2337/db14-0242
The paper
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., Minnion, J., Cuenco, J., Ghatei, M. A., Meeran, K., Tan, T. M., & Bloom, S. R. (2014). Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake. Diabetes. https://doi.org/10.2337/db14-0242

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.